Abstracts Archive - Page 397 of 2607 - ACR Meeting Abstracts

Abstract Number: 1165 • ACR Convergence 2023
Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America
Jenice Cheah¹, Sangmee Bae², Tiffany De Leon², Yuna Lee¹ and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Rheumatology, Los Angeles, CA, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) associated with antibodies to melanoma differentiation-associated protein 5 (MDA5 ab) in patients with dermatomyositis (DM) has been associated with a…
Abstract Number: 1174 • ACR Convergence 2023
Anti-HMGCR Immune-mediated Necrotising Myopathy: Calculation of Incidence and Confirmation of Low Malignancy Risk in Two Independent Cohorts. a Retrospective Case Review
Thomas Khoo¹, Xia Lyu², James Lilleker¹, Janine Lamb¹, Vidya Limaye³ and Hector Chinoy⁴, ¹University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Shanghai Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴The University of Manchester, Sale, United Kingdom
Background/Purpose: Immune-mediated necrotising myopathy (IMNM) is a rare complication of statin therapy, associated with the development of anti-HMGCR antibodies directed against the enzymatic target of…
Abstract Number: 1170 • ACR Convergence 2023
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
Abstract Number: 1159 • ACR Convergence 2023
Expanded Cytotoxic CD8+ T Cell Clones Characterize the Blood of Inclusion Body Myositis Patients
Miriam Fein¹, Laura Donlin¹, David Fernandez¹ and Lorien Shakib², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Inclusion body myositis (IBM) is an inflammatory myopathy, characterized by CD8+ T cell infiltration of muscle and patients present with progressive muscle weakness and…
Abstract Number: 1153 • ACR Convergence 2023
Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches
Manush Sondhi¹, Warda Maqsood² and Sarwat Umer³, ¹Louisiana State University, Shreveport, LA, ²LSU Health Science Center, Shreveport, LA, ³LSU Health Shreveport, Shreveport, LA
Background/Purpose: SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a relatively rare and often underdiagnosed inflammatory disorder. Its diagnosis can be challenging due to its…
Abstract Number: 1065 • ACR Convergence 2023
Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs
Ogheneyoma Akpoviroro¹, Nathan Sausers², Oghenetejiro Akpoviroro³, Queeneth Uwandu¹, Myriam Castagne⁴, Elga Rodrigues⁴, Lefulesele Khoalone¹, sara Humayun¹ and Jameson Woodard¹, ¹Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA, ²Pennsylvania State University, State College, PA, ³Mater Dei Hospital, Msida, Malta, ⁴Boston University, Boston, MA
Background/Purpose: Describe patients(pts) hospitalized with COVID-19C(C19) who were on disease modifying antirheumatic drugs (DMARDs) before admission(BA); assess if clinical outcomes differed from pts without BA…
Abstract Number: 1178 • ACR Convergence 2023
Self-Perceived Knowledge of Myositis Among Social Media Respondents- a Pilot Study on Twitter
Srijan Mittal¹, Vanshita Batra¹, Parikshit Sen², Saadia Sasha Ali³, Arpit Mago⁴, Mark Russell⁵, Eugenia Gkiaouraki⁶ and Rohit Aggarwal⁶, ¹Maulana Azad Medical College, New Delhi, India, ²Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ³King's College Hospital, Epsom, United Kingdom, ⁴Jawaharlal Nehru Medical College, Belgaum, India, ⁵King's College Hospital, London, United Kingdom, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis is a rare complex autoimmune disease that is less known and poorly understood, with increased effort required for education of practitioners, students, educators,…
Abstract Number: 1173 • ACR Convergence 2023
Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Toshimasa Shimizu¹, Haruna Matsuo², Tomohiro Koga³, Noriho Sakamoto⁴, Hiroshi Mukae¹ and Atsushi Kawakami¹, ¹Nagasaki University, Nagasaki, Japan, ²Nagasaki University, Nagasaki City, Japan, ³Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, ⁴Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a chronic inflammatory disorder involved in skeletal muscles. Interstitial lung disease (ILD) as an organ lesion is a common…
Abstract Number: 1182 • ACR Convergence 2023
Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies
Kristin Wipfler¹, Michael Feely², Gulsen Ozen³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Evo Alemao⁸ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Bellevue, NE, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸Janssen Pharmaceuticals, New Hope, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare, heterogeneous diseases characterized by chronic skeletal muscle inflammation and weakness. Initial conventional therapy is based on expert opinion…
Abstract Number: 1176 • ACR Convergence 2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Jiri Vencovsky¹, Jolie Feldman², Lisa McConnachie² and Brendan M. Johnson², ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…
Abstract Number: 1177 • ACR Convergence 2023
Anti-HMGCR Autoantibody Levels in the Follow-up of Statin-induced Immune-mediated Necrotizing Myopathy: Multicentric Study of 24 Patients
David Martinez-Lopez¹, Cristina Corrales Selaya², Diana Prieto-Peña², Piotr Szczesny³, Antonella Notarnicola⁴, Marcos Lopez-Hoyos⁵, Ricardo Blanco⁶, Ingrid Lundberg⁷ and Maryam Dastmalchi⁷, ¹Hospital de Sierrallana, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland; Department of Neurology, Medical University of Warsaw, Warsaw, Poland, ⁴Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁷Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden
Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies. It is characterized by elevated creatine kinase (CK) levels, and severe muscle…
Abstract Number: 1181 • ACR Convergence 2023
Real-World Myositis Antibody Frequency and Patient Awareness
Raisa Lomanto Silva¹, shiri keret², Akanksha Sharma³, Tanya Chandra⁴, Siamak Moghadam-Kia¹, Chester V. Oddis⁵ and Rohit Aggarwal⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Bnai Zion, Atlit, Israel, ³UPMC Mercy Hospital, Pittsburgh, PA, ⁴Georgetown University Hospital, Washington, DC, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis-specific antibodies (MSA) represent unique phenotypes in idiopathic inflammatory myopathies (IIM). Myositis-associated antibodies (MAA) most commonly occur in IIM overlap syndromes. MSA and MAA…
Abstract Number: 1166 • ACR Convergence 2023
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Emily He¹ and Vaneet Sandhu², ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA
Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…
Abstract Number: 1167 • ACR Convergence 2023
Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai³ and Moe Tokunaga(Sakamoto)³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
Abstract Number: 1187 • ACR Convergence 2023
Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA
Karin Nicholson¹, Edwin Sanchez¹, Wendy Wright², Joel Block³ and Richard Petruschke¹, ¹Haleon, Warren, NJ, ²Wright & Associates Family Healthcare, Amherst, NH, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Hand osteoarthritis (OA) is a frequently occurring form of OA characterized by symptoms including joint pain, stiffness, and swelling which affect performance of activities…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].